{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:58:18Z","timestamp":1787666298751,"version":"build-2736575974"},"reference-count":93,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:00:00Z","timestamp":1753574400000},"content-version":"am","delay-in-days":513,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.semnephrol.2024.151520","type":"journal-article","created":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T03:21:16Z","timestamp":1714879276000},"page":"151520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Challenges and Strategies in Implementing Novel Kidney Protective and Cardioprotective Therapies in Patients With Diabetes and Kidney Disease"],"prefix":"10.1016","volume":"44","author":[{"given":"Christine P.","family":"Limonte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio A.","family":"Lamprea-Montealegre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.semnephrol.2024.151520_bib0001","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","article-title":"A single number for advocacy and communication\u2014worldwide more than 850 million individuals have kidney diseases","volume":"96","author":"Jager","year":"2019","journal-title":"Kidney Int"},{"issue":"10225","key":"10.1016\/j.semnephrol.2024.151520_bib0002","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Bikbov","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151520_bib0003","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1186\/s12889-023-16130-8","article-title":"Global, regional, and national burden of kidney dysfunction from 1990 to 2019: a systematic analysis from the Global Burden of Disease Study 2019","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Public Health"},{"issue":"suppl 2","key":"10.1016\/j.semnephrol.2024.151520_bib0004","doi-asserted-by":"crossref","first-page":"ii121","DOI":"10.1093\/ndt\/gfw330","article-title":"The ascending rank of chronic kidney disease in the Global Burden of Disease Study","volume":"32","author":"Jager","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2024.151520_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151520_bib0006","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41581-022-00535-6","article-title":"Kidney and heart failure outcomes associated with SGLT2 inhibitor use","volume":"18","author":"van der Aart-van der Beek","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2024.151520_bib0007","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3389\/fphar.2020.00967","article-title":"GLP-1 receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms","volume":"11","author":"Kawanami","year":"2020","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151520_bib0008","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease\u2014mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"suppl 1","key":"10.1016\/j.semnephrol.2024.151520_bib0009","article-title":"Standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151520_bib0010","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int"},{"issue":"20","key":"10.1016\/j.semnephrol.2024.151520_bib0011","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151520_bib0012","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.semnephrol.2024.151520_bib0013","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.2337\/dc09-0191","article-title":"Cystatin C, albuminuria, and mortality among older adults with diabetes","volume":"32","author":"de Boer","year":"2009","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.semnephrol.2024.151520_bib0014","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1681\/ASN.2008121270","article-title":"Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes","volume":"20","author":"Ninomiya","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.semnephrol.2024.151520_bib0015","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.2337\/db08-1543","article-title":"The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes","volume":"58","author":"Groop","year":"2009","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151520_bib0016","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1007\/s00125-010-1860-3","article-title":"In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications study","volume":"53","author":"Orchard","year":"2010","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.semnephrol.2024.151520_bib0017","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.semnephrol.2024.151520_bib0018","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1093\/ndt\/gfs052","article-title":"Chronic kidney disease and life expectancy","volume":"27","author":"Turin","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"9854","key":"10.1016\/j.semnephrol.2024.151520_bib0019","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.semnephrol.2024.151520_bib0020","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/eurjhf\/hfq077","article-title":"Epidemiology and survival of the five stages of chronic kidney disease in a systolic heart failure population","volume":"12","author":"Hebert","year":"2010","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151520_bib0021","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cardfail.2007.03.011","article-title":"High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database","volume":"13","author":"Heywood","year":"2007","journal-title":"J Card Fail"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151520_bib0022","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2337\/dc13-2113","article-title":"Kidney disease and related findings in the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications study","volume":"37","author":"de Boer","year":"2014","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.semnephrol.2024.151520_bib0023","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.2215\/CJN.03700417","article-title":"Diabetes and CKD in the United States population, 2009-2014","volume":"12","author":"Zelnick","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.semnephrol.2024.151520_bib0024","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.2215\/CJN.02180311","article-title":"Metabolic syndrome and kidney disease: a systematic review and meta-analysis","volume":"6","author":"Thomas","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151520_bib0025","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/ndt\/gfl704","article-title":"Insulin resistance and the progression of IgA glomerulonephritis","volume":"22","author":"Kaartinen","year":"2007","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151520_bib0026","doi-asserted-by":"crossref","first-page":"643","DOI":"10.5414\/CNP71643","article-title":"Insulin resistance is a risk factor for the progression of chronic kidney disease","volume":"71","author":"Kobayashi","year":"2009","journal-title":"Clin Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151520_bib0027","first-page":"206","article-title":"Diabetes mellitus, a complex and heterogeneous disease, and the role of insulin resistance as a determinant of diabetic kidney disease","volume":"31","author":"Karalliedde","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151520_bib0028","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1053\/j.ajkd.2005.06.007","article-title":"Obesity and prevalent and incident CKD: the hypertension detection and follow-up program","volume":"46","author":"Kramer","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151520_bib0029","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1681\/ASN.2005060638","article-title":"Obesity and risk for chronic renal failure","volume":"17","author":"Ejerblad","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151520_bib0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.mcna.2012.10.010","article-title":"Obesity and diabetic kidney disease","volume":"97","author":"Maric-Bilkan","year":"2013","journal-title":"Med Clin North Am"},{"issue":"9","key":"10.1016\/j.semnephrol.2024.151520_bib0031","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1681\/ASN.2015070756","article-title":"Impaired glucose and insulin homeostasis in moderate-severe CKD","volume":"27","author":"de Boer","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151520_bib0032","doi-asserted-by":"crossref","first-page":"F1087","DOI":"10.1152\/ajprenal.00340.2016","article-title":"Insulin resistance in chronic kidney disease: a systematic review","volume":"311","author":"Spoto","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151520_bib0033","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.2337\/dc18-0831","article-title":"Trends and disparities in cardiovascular mortality among U.S. adults with and without self-reported diabetes, 1988-2015","volume":"41","author":"Cheng","year":"2018","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151520_bib0034","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10741-015-9515-6","article-title":"Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes","volume":"21","author":"Patel","year":"2016","journal-title":"Heart Fail Rev"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151520_bib0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1152\/physrev.00045.2011","article-title":"Mechanisms of diabetic complications","volume":"93","author":"Forbes","year":"2013","journal-title":"Physiol Rev"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151520_bib0036","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease","volume":"102","author":"Tuttle","year":"2022","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151520_bib0037","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jacc.2007.03.037","article-title":"The Framingham predictive instrument in chronic kidney disease","volume":"50","author":"Weiner","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.semnephrol.2024.151520_bib0038","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/dom.14698","article-title":"Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: a multinational, observational study across 12 countries","volume":"24","author":"Norhammar","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.semnephrol.2024.151520_bib0039","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.2215\/CJN.18641120","article-title":"Transforming the care of patients with diabetic kidney disease","volume":"16","author":"Brosius","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"17","key":"10.1016\/j.semnephrol.2024.151520_bib0040","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.semnephrol.2024.151520_bib0041","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021084","article-title":"Contemporary national patterns of eligibility and use of novel cardioprotective antihyperglycemic agents in type 2 diabetes mellitus","volume":"10","author":"Nargesi","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151520_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2022.108204","article-title":"Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes","volume":"36","author":"Limonte","year":"2022","journal-title":"J Diabetes Complications"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151520_bib0043","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.semnephrol.2024.151520_bib0044","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.4182","article-title":"Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US","volume":"2","author":"Eberly","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"10","key":"10.1016\/j.semnephrol.2024.151520_bib0045","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1111\/dom.15194","article-title":"Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD registry, 2019-2020","volume":"25","author":"Nicholas","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.semnephrol.2024.151520_bib0046","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.2337\/dc22-0614","article-title":"Prescription patterns of cardiovascular- and kidney-protective therapies among patients with type 2 diabetes and chronic kidney disease","volume":"45","author":"Lamprea-Montealegre","year":"2022","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1016\/j.semnephrol.2024.151520_bib0047","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1177\/2047487317729252","article-title":"Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: an NCDR\u00ae Research to Practice project","volume":"24","author":"Arnold","year":"2017","journal-title":"Eur J Prev Cardiol"},{"issue":"7","key":"10.1016\/j.semnephrol.2024.151520_bib0048","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamacardio.2023.1266","article-title":"Contemporary use of sodium-glucose cotransporter-2 inhibitor therapy among patients hospitalized for heart failure with reduced ejection fraction in the US: the Get With The Guidelines\u2014Heart Failure registry","volume":"8","author":"Pierce","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"9","key":"10.1016\/j.semnephrol.2024.151520_bib0049","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/jama.2022.13885","article-title":"Association of race and ethnicity with prescription of SGLT2 inhibitors and GLP1 receptor agonists among patients with type 2 diabetes in the Veterans Health Administration system","volume":"328","author":"Lamprea-Montealegre","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151520_bib0050","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/j.ajkd.2022.11.017","article-title":"Predictors, disparities, and facility-level variation: SGLT2 inhibitor prescription among US veterans with CKD","volume":"82","author":"Gregg","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2024.151520_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109118","article-title":"IDF Diabetes Atlas: global estimates of undiagnosed diabetes in adults for 2021","volume":"183","author":"Ogurtsova","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.semnephrol.2024.151520_bib0052","unstructured":"Centers for Disease Control and Prevention. National Diabetes Statistics Report: estimates of diabetes and its burden in the United States. 2022. Accessed October 15, 2023. https:\/\/www.cdc.gov\/diabetes\/data\/statistics-report\/index.html"},{"key":"10.1016\/j.semnephrol.2024.151520_bib0053","series-title":"2022 USRDS Annual Data Report: Epidemiology of kidney disease in the United States","year":"2022"},{"issue":"9","key":"10.1016\/j.semnephrol.2024.151520_bib0054","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2337\/dc21-0723","article-title":"Chronic kidney disease testing among at-risk adults in the U.S. remains low: real-world evidence from a national laboratory database","volume":"44","author":"Alfego","year":"2021","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.semnephrol.2024.151520_bib0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18169","article-title":"Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry","volume":"2","author":"Tuttle","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151520_bib0056","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1053\/j.ajkd.2020.01.007","article-title":"CKD awareness among US adults by future risk of kidney failure","volume":"76","author":"Chu","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1016\/j.semnephrol.2024.151520_bib0057","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221325","article-title":"Primary care physicians\u2019 perceptions of barriers and facilitators to management of chronic kidney disease: a mixed methods study","volume":"14","author":"Sperati","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2024.151520_bib0058","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ahj.2020.03.017","article-title":"Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits","volume":"224","author":"Gao","year":"2020","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151520_bib0059","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"19","key":"10.1016\/j.semnephrol.2024.151520_bib0060","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1161\/CIRCULATIONAHA.119.042685","article-title":"Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus","volume":"140","author":"Berg","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151520_bib0061","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/ndt\/gfac140","article-title":"High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database","volume":"38","author":"Fried","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1016\/j.semnephrol.2024.151520_bib0062","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/ndt\/gfaa300","article-title":"Renin-angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease","volume":"36","author":"Walther","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151520_bib0063","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00592-022-02015-6","article-title":"SGLT-2 inhibitors and euglycemic diabetic ketoacidosis\/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment","volume":"60","author":"He","year":"2023","journal-title":"Acta Diabetol"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151520_bib0064","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001238","article-title":"Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation","volume":"8","author":"McGovern","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151520_bib0065","doi-asserted-by":"crossref","first-page":"876","DOI":"10.3390\/biomedicines11030876","article-title":"Predictors and outcomes of SGLT2 inhibitor discontinuation in a real-world population after hospitalization for heart failure","volume":"11","author":"Nakagaito","year":"2023","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151520_bib0066","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/jcpt.13205","article-title":"Discontinuation rate and reason for discontinuation after sodium-glucose cotransporter 2 inhibitor prescription in real clinical practice","volume":"45","author":"Kim","year":"2020","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151520_bib0067","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.35792","article-title":"Comparison of diabetes medications used by adults with commercial insurance vs Medicare Advantage, 2016 to 2019","volume":"4","author":"McCoy","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.semnephrol.2024.151520_bib0068","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.4205","article-title":"Coverage, formulary restrictions, and affordability of sodium-glucose cotransporter 2 inhibitors by US insurance plan types","volume":"2","author":"Tummalapalli","year":"2021","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.semnephrol.2024.151520_bib0069","unstructured":"Karpman M, Blavin F, McMorrow S, O'Brien C. In the years before the COVID-19 pandemic, nearly 13 million adults delayed or did not get needed prescription drugs because of costs: findings from the 2018-19 Medical Expenditure Panel Survey, Urban Institute https:\/\/www.urban.org\/research\/publication\/years-covid-19-pandemic-nearly-13-million-adults-delayed-or-did-not-get-needed-prescription-drugs-because-costs."},{"issue":"7","key":"10.1016\/j.semnephrol.2024.151520_bib0070","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2215\/CJN.02980322","article-title":"Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease","volume":"17","author":"Tuttle","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151520_bib0071","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/1077558711430690","article-title":"A compilation of strategies for implementing clinical innovations in health and mental health","volume":"69","author":"Powell","year":"2012","journal-title":"Med Care Res Rev"},{"key":"10.1016\/j.semnephrol.2024.151520_bib0072","doi-asserted-by":"crossref","DOI":"10.1177\/20543581221081207","article-title":"A unique multi- and interdisciplinary cardiology-renal-endocrine clinic: a description and assessment of outcomes","volume":"9","author":"Dubrofsky","year":"2022","journal-title":"Can J Kidney Health Dis"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151520_bib0073","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.007264","article-title":"Cardio-renal-metabolic care models: toward achieving effective interdisciplinary care","volume":"13","author":"Rangaswami","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151520_bib0074","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11892-020-1292-5","article-title":"A systematic review of cost-effectiveness of sodium-glucose cotransporter inhibitors for type 2 diabetes","volume":"20","author":"Yoshida","year":"2020","journal-title":"Curr Diab Rep"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151520_bib0075","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ekir.2021.10.022","article-title":"Nephrologists\u2019 perspectives on gender disparities in CKD and dialysis","volume":"7","author":"Tong","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.semnephrol.2024.151520_bib0076","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3389\/fpubh.2020.00134","article-title":"An extension of RE-AIM to enhance sustainability: addressing dynamic context and promoting health equity over time","volume":"8","author":"Shelton","year":"2020","journal-title":"Front Public Health"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151520_bib0077","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12939-019-0984-4","article-title":"Conceptual framework of equity-focused implementation research for health programs (EquIR)","volume":"18","author":"Eslava-Schmalbach","year":"2019","journal-title":"Int J Equity Health"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151520_bib0078","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-020-4975-3","article-title":"Reframing implementation science to address inequities in healthcare delivery","volume":"20","author":"Baumann","year":"2020","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151520_bib0079","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-5908-6-42","article-title":"The behaviour change wheel: a new method for characterising and designing behaviour change interventions","volume":"6","author":"Michie","year":"2011","journal-title":"Implement Sci"},{"key":"10.1016\/j.semnephrol.2024.151520_bib0080","doi-asserted-by":"crossref","unstructured":"Holtrop JS, Estabrooks PA, Gaglio B, et al. Understanding and applying the RE-AIM framework: clarifications and resources. J Clin Transl Sci. 2021;5(1):e126. doi:10.1017\/cts.2021.789","DOI":"10.1017\/cts.2021.789"},{"issue":"7","key":"10.1016\/j.semnephrol.2024.151520_bib0081","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.26230","article-title":"Estimated prevalence and testing for albuminuria in US adults at risk for chronic kidney disease","volume":"6","author":"Chu","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"10407","key":"10.1016\/j.semnephrol.2024.151520_bib0082","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/S0140-6736(23)00876-0","article-title":"Participation rate and yield of two home-based screening methods to detect increased albuminuria in the general population in the Netherlands (THOMAS): a prospective, randomised, open-label implementation study","volume":"402","author":"van Mil","year":"2023","journal-title":"Lancet"},{"issue":"10407","key":"10.1016\/j.semnephrol.2024.151520_bib0083","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0140-6736(23)01140-6","article-title":"Population-wide albuminuria screening: implications for CKD detection and management","volume":"402","author":"Lamprea-Montealegre","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151520_bib0084","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMoa2208275","article-title":"Polypill strategy in secondary cardiovascular prevention","volume":"387","author":"Castellano","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151520_bib0085","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S2213-8587(21)00318-1","article-title":"Diabetes and the WHO Model List of Essential Medicines","volume":"10","author":"Khan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151520_bib0086","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","article-title":"Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease","volume":"18","author":"Matsushita","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"10.1016\/j.semnephrol.2024.151520_bib0087","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.semnephrol.2024.151520_bib0088","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.semnephrol.2024.151520_bib0089","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.semnephrol.2024.151520_bib0090","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.semnephrol.2024.151520_bib0091","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151520_bib0092","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.semnephrol.2024.151520_bib0093","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol Dial Transplant"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929524000408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929524000408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T14:52:00Z","timestamp":1748357520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929524000408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0270929524000408"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2024.151520","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges and Strategies in Implementing Novel Kidney Protective and Cardioprotective Therapies in Patients With Diabetes and Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2024.151520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151520"}}